<DOC>
	<DOCNO>NCT01513759</DOCNO>
	<brief_summary>The purpose study determine EKOS EkoSonic® Endovascular Device use conjunction recombinant t-PA treatment acute pulmonary embolism ( PE ) decrease ratio RV LV diameter within 48 ± 6 hour patient massive submassive PE .</brief_summary>
	<brief_title>A Prospective , Single-arm , Multi-center Trial EkoSonic® Endovascular System Activase Treatment Acute Pulmonary Embolism ( PE ) .</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>CT evidence proximal PE ( fill defect least one main segmental pulmonary artery ) AND Age ≥ 18 year AND PE symptom duration ≤14 day AND Informed consent obtain subject Legally Authorized Representative ( LAR ) AND Massive PE ( syncope , systemic arterial hypotension , cardiogenic shock , resuscitate cardiac arrest ) OR Submassive PE ( RV diametertoLV diameter ≥ 0.9 contrastenhanced chest CT ) Stroke transient ischemic attack ( TIA ) , head trauma , active intracranial intraspinal disease within one year Recent ( within one month ) active bleed major organ Hematocrit &lt; 30 % Platelets &lt; 100 thousand/μL INR &gt; 3 aPTT &gt; 50 second anticoagulant Major surgery within seven day Serum creatinine &gt; 2 mg/dL Clinician deem highrisk catastrophic bleed History heparininduced thrombocytopenia ( HIT ) Pregnancy Catheterbased pharmacomechanical treatment pulmonary embolism within 3 day study enrollment Systolic blood pressure le 80 mm Hg despite vasopressor inotropic support Cardiac arrest ( include pulseless electrical activity asystole ) require active cardiopulmonary resuscitation ( CPR ) Evidence irreversible neurological compromise Life expectancy &lt; 30 day Use thrombolytic glycoprotein IIb/IIIa antagonist within 3 day prior inclusion study Previous enrollment SEATTLE study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Fibrinolysis</keyword>
	<keyword>catheter direct fibrinolysis</keyword>
	<keyword>ultrasound accelerate fibrinolysis</keyword>
	<keyword>recombinant t-PA</keyword>
	<keyword>Activase</keyword>
</DOC>